2.83
+0(+0.00%)
Currency In USD
| Previous Close | 2.83 |
| Open | 2.84 |
| Day High | 2.87 |
| Day Low | 2.76 |
| 52-Week High | 3.22 |
| 52-Week Low | 1.8 |
| Volume | 604,860 |
| Average Volume | 510,422 |
| Market Cap | 163.86M |
| PE | 10.48 |
| EPS | 0.27 |
| Moving Average 50 Days | 2.62 |
| Moving Average 200 Days | 2.35 |
| Change | 0 |
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacteria
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 28, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacteria
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
GlobeNewswire Inc.
Nov 04, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacteri